MaxCyte chief commercial officer Ali Soleymannezhad sells $3,850 in stock

Published 20/03/2025, 23:52
MaxCyte chief commercial officer Ali Soleymannezhad sells $3,850 in stock

Ali Soleymannezhad, the Chief Commercial Officer of MaxCyte, Inc. (NASDAQ:MXCT), a biotechnology company with a market capitalization of $345 million, recently sold shares of the company’s common stock. According to InvestingPro data, the stock is currently trading near its Fair Value, with analysts maintaining a strong buy consensus. The sale, which took place on March 18, 2025, involved 1,211 shares at a weighted average price of $3.1793 per share, totaling approximately $3,850. Following this transaction, Soleymannezhad retains ownership of 59,439 shares. The stock has seen significant volatility, trading between $2.76 and $5.26 over the past 52 weeks.

The shares were sold to cover tax withholding obligations upon the vesting of previously granted restricted stock units (RSUs). This transaction was automatically executed and does not represent a discretionary trade by Soleymannezhad. The shares were sold in multiple transactions at prices ranging from $3.14 to $3.215. For deeper insights into insider trading patterns and additional ProTips about MXCT, including its strong balance sheet position, check out the comprehensive research report available on InvestingPro.

In other recent news, MaxCyte Inc. has announced its fourth-quarter earnings for 2024, revealing a total revenue of $8.7 million, marking a significant 45% decline from the same period in the previous year. Despite the revenue drop, the company reported an earnings per share (EPS) of -0.1, surpassing the forecasted -0.12. The company has projected an 8-15% growth in core revenue for 2025, factoring in contributions from the newly acquired SeQure Dx business. However, this projection falls short of Wall Street expectations, leading to a cautious outlook from analysts. Stifel and BTIG have both adjusted their price targets for MaxCyte, with Stifel lowering it to $9 while maintaining a Buy rating, and BTIG reducing it to $6, also with a Buy rating. The analysts have noted macroeconomic and funding uncertainties as influencing factors in their revised targets. MaxCyte ended 2024 with $190.3 million in cash and no debt, maintaining a strong financial position despite the challenges. The company also highlighted the potential economic benefits from its strategic platform license agreements, with 28 active agreements at the end of the year.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.